Demographics of ALL patients with asparaginase hypersensitivity data
| Characteristics . | Treatment protocol . | |||||
|---|---|---|---|---|---|---|
| SJCRH total XIIIA (%) . | SJCRH total XV (%) . | SJCRH total XVI (%) . | POG 9906 (%) . | COG AALL0232 (%) . | Combined . | |
| Sample size (n) | 154 (4.7%)* | 498 (15.1%)* | 271 (8.2%)* | 222 (6.7%)* | 2163 (65.4%)* | 3308* |
| Age | 43 (28.3%),† 7.1 | 126 (25.3%),† 7.0 | 73 (26.9%),† 7.2 | 146 (65.8%),† 11.2 | 1372 (63.4%),† 10.1 | 1760 (53.2%),† 9.3 |
| (n ≥ 10, mean age) | ||||||
| Gender | 90 (58.4%)† | 279 (56.0%)† | 156 (57.6%)† | 150 (67.6%)† | 1183 (54.7%)† | 1858 (56.2%)† |
| (n, Male) | ||||||
| Ancestry‡ | ||||||
| European | 99 (75.6%)† | 322 (66.1%)† | 187 (69.5%)† | 122 (55.0%)† | 1,215 (56.2%)† | 1959 (59.5%)† |
| Hispanic | 11 (8.4%)† | 66 (13.6%)† | 21 (7.8%)† | 64 (28.8%)† | 560 (25.9%)† | 725 (22.0%)† |
| African | 19 (17.6%)† | 72 (14.8%)† | 11 (4.1%)† | 14 (6.3%)† | 134 (6.2%)† | 254 (7.7%)† |
| Asian | 0 (0.0%)† | 6 (1.2%)† | 1 (0.4%)† | 4 (1.8%)† | 42 (1.9%)† | 53 (1.6%)† |
| Other | 2 (1.5%)† | 21 (4.3%)† | 49 (18.2%)† | 18 (8.1%)† | 212 (9.8%)† | 302 (9.2%)† |
| ALL lineage§ | 130 (85.5%)† | 423 (84.9%)† | 225 (83.0%)† | 222 (100.0%)† | 2153 (100.0%)† | 3153 (95.6%)† |
| (n, B-ALL) | ||||||
| Characteristics . | Treatment protocol . | |||||
|---|---|---|---|---|---|---|
| SJCRH total XIIIA (%) . | SJCRH total XV (%) . | SJCRH total XVI (%) . | POG 9906 (%) . | COG AALL0232 (%) . | Combined . | |
| Sample size (n) | 154 (4.7%)* | 498 (15.1%)* | 271 (8.2%)* | 222 (6.7%)* | 2163 (65.4%)* | 3308* |
| Age | 43 (28.3%),† 7.1 | 126 (25.3%),† 7.0 | 73 (26.9%),† 7.2 | 146 (65.8%),† 11.2 | 1372 (63.4%),† 10.1 | 1760 (53.2%),† 9.3 |
| (n ≥ 10, mean age) | ||||||
| Gender | 90 (58.4%)† | 279 (56.0%)† | 156 (57.6%)† | 150 (67.6%)† | 1183 (54.7%)† | 1858 (56.2%)† |
| (n, Male) | ||||||
| Ancestry‡ | ||||||
| European | 99 (75.6%)† | 322 (66.1%)† | 187 (69.5%)† | 122 (55.0%)† | 1,215 (56.2%)† | 1959 (59.5%)† |
| Hispanic | 11 (8.4%)† | 66 (13.6%)† | 21 (7.8%)† | 64 (28.8%)† | 560 (25.9%)† | 725 (22.0%)† |
| African | 19 (17.6%)† | 72 (14.8%)† | 11 (4.1%)† | 14 (6.3%)† | 134 (6.2%)† | 254 (7.7%)† |
| Asian | 0 (0.0%)† | 6 (1.2%)† | 1 (0.4%)† | 4 (1.8%)† | 42 (1.9%)† | 53 (1.6%)† |
| Other | 2 (1.5%)† | 21 (4.3%)† | 49 (18.2%)† | 18 (8.1%)† | 212 (9.8%)† | 302 (9.2%)† |
| ALL lineage§ | 130 (85.5%)† | 423 (84.9%)† | 225 (83.0%)† | 222 (100.0%)† | 2153 (100.0%)† | 3153 (95.6%)† |
| (n, B-ALL) | ||||||
The percentage of patients enrolled within each protocol relative to the total number of patients enrolled across all protocols.
The percentage of patients with the characteristic described in the first column.
The genetic ancestry of patients with available genotyping was estimated using STRUCTURE, with numbers of patients indicated for those in the European-ancestry group defined as >90% Northern European ancestry (CEU), Asian-ancestry group as >90% East Asian ancestry (CHB/JBT), African-ancestry group as >70% West African ancestry (YRI), Hispanics as >10% Native American ancestry and greater than % of African ancestry, and others as those outside the above boundaries.
ALL lineage refers to the ALL immunophenotype; patients without B-lineage ALL had T-cell ALL and were only enrolled on SJCRH treatment protocols.